Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514421 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02514421 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 6 participants.
The verdict
NCT02514421, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration. Electroporation uses an electric current to produce holes in pancreatic tumor, which causes the tumor cells to die or take up a higher concentration of administered chemotherapy agent. This study will test the safety and look at the effect of electrochemotherapy in the treatment of stage III pancreatic adenocarcinoma. This study will also help to find the safest and most effective amount of electroporation voltage to apply to this type of tumor.
Interventions
- DRUG nab-paclitaxel
- DRUG gemcitabine
- DEVICE Electroporation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514421
The ClinicalTrials.gov registry entry for NCT02514421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nab-paclitaxel is the first listed.
NCT02514421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02514421 about?
NCT02514421 is a clinical study titled "Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma". The purpose of this study is to see how well electrochemotherapy works at treating people with Stage III pancreatic adenocarcinoma. Electrochemotherapy is a treatment that combines electroporation and chemotherapy administration. Electroporation uses an electric current to produce holes in pancreati...
What is the current status of trial NCT02514421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-07. Estimated completion is 2017-04-18.
What interventions are being tested in trial NCT02514421?
The interventions under investigation include: nab-paclitaxel (DRUG), gemcitabine (DRUG), Electroporation (DEVICE).
Who is sponsoring clinical trial NCT02514421?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.